title: Biomarkers predicting chemotherapy response in head and neck squamous cell carcinoma: a review.
abstract: BACKGROUND
  Biomarkers are increasingly being used in many cancers to select patients for oncological treatment paradigms based on their inherent genetic properties. However, in head and neck cancers, there are no personalised therapies available outside the context of a clinical trial. A number of studies suggest there are intrinsic tumour properties of head and neck cancers that affect their response to chemotherapeutic agents. This paper aimed to review their evidence base.
  
  
  METHODS
  A narrative review was conducted following a search of the PubMed database.
  
  
  CONCLUSIONS
  The review identified a number of biomarkers predicting response to chemotherapy in head and neck cancers. The paper discusses these in detail, and explores where future research could be directed in order to deliver personalised therapies for patients with head and neck cancers.
authors.affiliation: Department of Otolaryngology - Head and Neck Surgery,Freeman Hospital,Newcastle upon Tyne,UK.
authors.forename: B
authors.initials: B
authors.lastname: Cosway
authors.affiliation: Department of Otolaryngology - Head and Neck Surgery,Freeman Hospital,Newcastle upon Tyne,UK.
authors.forename: V
authors.initials: V
authors.lastname: Paleri
authors.affiliation: Department of Otolaryngology - Head and Neck Surgery,Freeman Hospital,Newcastle upon Tyne,UK.
authors.forename: J
authors.initials: J
authors.lastname: Wilson
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D019938:Cyclin D1 / Q000097:blood; D066246:ErbB Receptors / Q000097:blood; D019317:Evidence-Based Medicine; D005786:Gene Expression Regulation; D005982:Glutathione Transferase / Q000097:blood; D006258:Head and Neck Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D009154:Mutation; D011110:Polymorphism, Genetic; D011237:Predictive Value of Tests; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012680:Sensitivity and Specificity; D014404:Tubulin / Q000097:blood; D016159:Tumor Suppressor Protein p53 / Q000097:blood*; D051020:bcl-X Protein / Q000097:blood*
chemical_list: D000970:Antineoplastic Agents; C494811:BCL2L1 protein, human; D014408:Biomarkers, Tumor; D014404:Tubulin; D016159:Tumor Suppressor Protein p53; D051020:bcl-X Protein; D019938:Cyclin D1; D005982:Glutathione Transferase; D066246:ErbB Receptors
keywords: Biological Markers; Induction Chemotherapy; Otorhinolaryngological Neoplasms